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ABSTRACT
Background: The effect of inhaled corticosteroid (ICS) on the bone status of asthmatic patients is still uncar-
tain, becuase it can differ by race and because there have been few cases in Japan. In this study, the bone
status of ICS users with asthma was evaluated in an actual clinical setting in Japan.
Methods: In 7 participating hospitals, ICS users with asthma and control subjects were age- and gender-
matched and recruited into this study. To assess bone status, ultrasound measurements of each individual’s
calcaneus were made using an AOS-100. The ratio of the osteo sono-assessment index (OSI) to the average
OSI corrected for age and gender was denoted as %OSI and used for quantitative assessment. The second
%OSI measurement was performed 6 months after the first %OSI one. During the study period, individual treat-
ment remained unchanged.
Results: There were no significant differences in the 1st and 2nd %OSI between the ICS users and control
subjects. However, the 2nd %OSI significantly decreased compared with 1st %OSI in female ICS users, al-
though there were no significant changes in the male and female control subjects and male ICS users.
Conclusions: The 6 month manegement of asthma in the actual clinical setting, including regular ICS use,
might have a harmful influence on the bone status of female asthmatic patients. It may be necessary to man-
age and treat female patients for potent corticosteroid-induced osteoporosis, although further analyses of bone
status in asthma patient ICS users will be required.
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ABBREVIATIONS
BDP, hydrofluoroalkane-beclometasone; BMD, bone marrow density; BUD, budesonide; COPD, chronic ob-
structive pulmonary disease; DEXA, dual-energy X-ray absorption-metry; FP, fluticasone; ICS, inhaled corti-
costeroid; LABA, inhaled long-acting beta agonist; LTRA, leukotriene receptor antagonist; OSI, osteo sono-
assessment index; OSRT, oral sustained-released theophylline; SOS, speed of sound; TI, transmission index;
YAM, bone marrow density of young adult meaning.
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INTRODUCTION
Guidelines in various countries recommend inhaled
corticosteroids (ICS) for the primary treatment of
bronchial asthma in adults.1-3 The spread of ICS use
has led to dramatic improvements in the manage-
ment of asthma in Japan.4,5 However, several poten-
tial adverse effects of ICS have been reported,6 which
have been divided into systemic adverse effects7 and
local ones.8 With wide and longitudinal use of ICS,
the former is an important factor in the ICS treatment
of asthma. Recently, an increasing body of literature
suggests the adverse effects of ICS use on bone
status are one of the most important problems in the
management of asthma.9-27
It is known that impaired bone status can lead to
osteoporosis, which may result in an unexpected
pathological fracture of the femoral neck, have an im-
pact on patients’ quality of life, and frequently is a di-
rect cause of death.28-31 In this sense, it is essential, if
any adverse effects of ICS use on bone status can ex-
ist. Moreover, it is now possible to adequately treat
osteoporosis, whether idiopathic or secondary to cor-
ticosteroid use. In such management, the assessment
of bone status is beneficial in the prediction of patho-
logical fracture.32,33
The adverse effects of ICS on bone status have
been frequently studied as mentioned above, and it
has been reported in some major studies, including 4
double-blinded placebo controlled studies, that there
were few effects on bone status with regular admini-
stration of ICS,9-18 whereas others have reported that
ICS use influenced on the bone status.17-27 Therefore,
the main stream of the relationship between ICS use
and its effect on bone status is not likely to exist.
However, we thought that the conclusion have not
been established completely, because bone status
can differ with several factors, such as race,34,35 and
because there have been a few studies on the effect of
ICS on bone status in Japan. In one of these report in
Japan,18 there were no control group and case num-
bers were relatively small. It is necessary, therefore,
to clarify the adverse effect on bone status in a Japa-
nese clinical setting with large case and control num-
bers. To evaluate bone status, a new method, that of
ultrasound measurement, has been developed and
has been reported as easy to use.36-40 In the present
study, on the assessement of the bone status of asth-
matic patients, we used this ultrasound measurement
method, because a possible large case numbers
could be recruited due to both the easeness to handle
and no adverse effects of radiation.
METHODS
This study was performed with the approval of the
Ethics Committees of the School of Medicine of Nii-
gata University in Niigata Prefecture, Japan, as well
as those of each participating institution, based on the
Ethical Principles for Medical Research Involving Hu-
man Subjects (the Declaration of Helsinki). The sub-
jects gave a written informed consent and patient ano-
nymity were preserved using documents and method
approved by the ethical review committee of the hos-
pital. The study involved the following seven hospi-
tals: Prefectural Muikamachi Hospital, Prefectural
Yoshida Hospital, Nagaoka Chuo General Hospital,
Prefectural Kamo Hospital, Prefectural Tsugawa Hos-
pital, Nagaoka Red Cross Hospital and Nanbugo Gen-
eral Hospital. The study was performed over 22
months from September 2005 to June 2007. Subjects
were ICS users (aged 16 years and over) with bron-
chial asthma who regularly visited the participating
institutes for asthma management (typically once or
twice per month) and controls were patients with
other diseases or volunteers at the same institutes.
To assess bone status, ultrasound measurements
of the right calcaneus were carried out using an AOS-
100 (Aloka Co. Ltd, Tokyo, Japan). The AOS-100
measures the ultrasound properties of the calcaneus
by a transmission technique using a pair of unfocused
broadband ultrasound transducers, positioned on
each side of the calcaneus. Three ultrasonic parame-
ters are obtained using the AOS-100 system. These
are the speed of sound (SOS), the transmission index
(TI) and the osteo sono-assessment index (OSI). OSI,
calculated as (SOS)2 x TI, which has been reported
to be well-correlated to bone marrow density (BMD),
as measured by dual-energy X-ray absorption-
metry,32 is a commonly-used as an indicator of bone
status.
In this study, a quantitative assessment of bone
status with AOS-100 was performed twice in each
subject. The second OSI was measured 6 months af-
ter the first one. The ratio of the OSI in the right indi-
vidual calcaneus to the average OSI, corrected for
age and gender was denoted as %OSI and used for
quantitative assessment. Other clinical information,
including patients’ backgrounds, was recorded at the
first assessment of bone status.
Results are expressed as arithmetic means (±SD)
for continuous variables. A Mann-Whitney U-test was
used to test the equality of distributions of the con-
tinuous variables. The differences between dichoto-
mous variables were analyzed with a chi-square test.
A pairwise comparison was performed using Wil-
coxon’s rank sum test for the significance level. All
statistical analyses were performed with the statistical
software StatView 5.0 PowerPC version (SAS Insti-
tute Inc., Cary, NC, USA). For all statistical analyses,
a P-value < 0.05 was considered to be significant.
RESULTS
BACKGROUND IN CONTROL SUBJECTS AND
ICS USERS WITH BRONCHIAL ASTHMA
The backgrounds of the ICS users with bronchial
asthma and control subjects are summarized in Table
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Table　1　Background in control and ICS users
control ICS users P value
gender (male/female) 43/50 84/114 0.5409
age (year: mean +/- SD) 60.6 +/- 12.4 59.1 +/- 15.8 0.8796
age of male (year: mean +/- SD) 63.8 +/- 10.7 60.9 +/- 15.2 0.6882
age of female (year: mean +/- SD) 57.9 +/- 13.2 57.8 +/- 16.1 0.8709
ICS, inhaled corticosteroid.
Table　2　Complications in control cases
male female
COPD 13  0
mycobacterial infection  1  2
pneumoconiosis  3  0
sleep apnea syndrome 10  2
hypertension  5 10
sarcoidosis  0  1
bronchiectasis  0  4
neurosis  0  1
depression  0  1
diabetes mellitus  0  1
1. The control subjects and ICS users with asthma
were composed of 43 males and 50 females, and 84
males and 114 females, respectively. The mean ages
of control subjects and ICS users were 60.6 +- 12.4
and 59.1 +- 15.8 years. There were no significant dif-
ferences in terms of gender or age in the two groups.
The mean ages of male control subjects and ICS us-
ers, and female control subjects and ICS users were
63.8 +- 10.7 and 60.9 +- 15.2, 57.9 +- 13.2 and 57.8
+- 16.1, respectively. There were no significant dif-
ferences in terms age between male control subjects
and ICS users and between females in the two
groups. As for the systemic corticosterod user, there
were 2 male and 2 female users.
COMPLICATIONS IN CONTROL SUBJECTS
Table 2 shows a summary of complications in the 93
control subjects. Of the 43 male control subjects, 13
cases had chronic obstructive pulmonary disease
(COPD), 10 cases had sleep apnea syndrome, 5 cases
had hypertension, 3 cases had pneumoconiosis and 1
case had mycobacterial infection. There were 10 hy-
pertension cases, 4 bronchiectasis cases, 2 mycobac-
terial infection cases, 2 sleep apnea syndrome cases,
1 sarcoidosis case, 1 neurosis case, 1 depression case
and 1 diabetes mellitus case amongst the female con-
trols. However, there were no potent medicines that
can affect bone status, such as corticosteroid, admin-
istrated for these pathological conditions.
AGE, DISEASE DURATION, TYPE, SEVERITY
AND TREATMENT IN ICS USERS WITH ASTHMA
Table 3 shows the age, disease duration, type, sever-
ity and treatment in male and female ICS users. The
type of asthma was decided in accordance with the
elevation in serum total IgE or detection of specific
IgE for allergens. Age and duration of disease was
60.9 +- 15.2 and 8.7 +- 7.1, 57.8 +- 16.1 and 8.9 +-
8.1 years in male ICS users and in female ICS users,
respectively. The proportion of patients by disease
type and disease severity amongst male and female
ICS users was 42.6%, 53.6% and 50.9%, 43.9% (atopic
type, non-atopic type), and 1.2%, 39.3%, 31.0%, 9.5%
and 4.4%, 35.1%, 41.2%, 3.5% (step 1, step 2, step 3,
step 4), respectively. There were no significant differ-
ences in terms of age, disease duration, type of
asthma, and disease severity between the male and
female ICS users. Of the male ICS users, 78.6% used
fluticasone (FP), 8.3% used budesonide (BUD) and
10.7% used hydrofluoroalkane-beclometasone (BDP),
and the percentages of those using inhaled long-
acting beta agonists (LABAs), leukotriene receptor
antagonists (LTRAs) and oral sustained-released the-
ophylline (OSRT) were 44.0%, 35.7% and 39.3%, re-
spectively. Of the female ICS users, 72.8% used FP,
16.7% used BUD and 8.8% used BDP, and the use rate
of LABAs, LTRAs and OSRT was 41.2%, 41.2% and
38.6%, respectively. The doses of administered ICS,
which was calculated as FP (mean +- SD) based on
Japanese Society of Allergology in male and female
ICS users, were 460 +- 214 and 392 +- 181 (μgday),
respectively, and the ICS doses administered to male
users were significantly higher than those adminis-
tered to females. There were no significant differ-
ences in the distribution of the types of ICS, or in the
percentage of those using LABAs, LTRAs and OSRT.
COMPARISON OF %OSI BETWEEN THE CON-
TROL SUBJECTS AND ICS USERS WITH BRON-
CHIAL ASTHMA AND CHANGES FROM 1ST
%OSI TO 2ND %OSI IN THE CONTROL SUB-
JECTS AND ICS USERS WITH BRONCHIAL
ASTHMA
First-time measured OSI (1st %OSI) and second-time
measured OSI (2nd %OSI) were 100.7 +- 12.0 and
100.5 +- 13.5% for all control subjects, and 102.8 +-
12.0 and 102.1 +- 11.0% for the ICS users, respec-
tively (Table 4a). There were no significant differ-
ences in first-time measured OSI (1st %OSI) and
second-time measured OSI (2nd %OSI) between the
two groups (Table 4a). In the male subjects and the
Sasagawa M et al.
462 Allergology International Vol 60, No4, 2011 www.jsaweb.jp
Table　3　Age, disease duration, type, severity and treatment in ICS users with asthma
male ICS users (84 cases) female ICS users (114 cases) P value
age (year: mean +/- SD) 60.9 +/- 15.2 57.8 +/- 16.1 P = 0.1975
duration (year: mean +/- SD) 8.7 +/- 7.1 8.9 +/- 8.1 P = 0.9288
type (%: atopic/nonatopic) 42.9/53.6 50.9/43.9 P = 0.2654
severity (%: step1/2/3/4) 1.2/39.3/31.0/9.5 4.4/35.1/41.2/3.5 P = 0.1064
used ICS (%: FP/BUD/BDP) 78.6/8.3/10.7 72.8/16.7/8.8 P = 0.2274
doses of ICS calculated as FP (μg/day) 460 +/- 214 392 +/- 181 P = 0.0308
% use of LABA 44.0 41.2 P = 0.8598
% use of LTRA 35.7 41.2 P = 0.5288
% use of OSRT 39.3 38.6 P = 0.9271
ICS, inhaled corticosteroid; FP, fl uticasone propionate; BUD, budesonide; BDP, hydrofl uoroalkane-beclometasone; LABA, inhaled long-
acting beta agonist; LTRA, leukotrien receptor antagonist; OSRT, oral sustained-released theophylline.
Table  4a　%OSI and its change in control and ICS users
control ICS users P value (control v.s. ICS users)
1st %OSI 100.7 +/- 12.0 102.8 +/- 12.0 0.1264
2nd %OSI 100.5 +/- 13.5 102.1 +/- 11.0 0.1204
P value (1st v.s. 2nd %OSI) 0.3788 0.4009
ICS, inhaled corticosteroid; OSI, osteo sono-assessment index.
Table  4b　%OSI and its change in male control and male ICS users
control ICS users P value (control v.s. ICS users)
1st %OSI 98.3 +/- 12.2 101.4 +/- 13.9 0.2602
2nd %OSI 97.7 +/- 13.4 101.8 +/- 12.4 0.0548
P value (1st v.s. 2nd %OSI) 0.2213 0.1669
ICS, inhaled corticosteroid; OSI, osteo sono-assessment index.
Table　4c　%OSI and its change in female control and female ICS users
control ICS users P value (control v.s. ICS users)
1st %OSI 102.8 +/- 11.5  103.9 +/- 10.4 0.7710
2nd %OSI 102.8 +/- 13.4 102.3 +/- 9.9 0.8709
P value (1st v.s. 2nd %OSI) 0.9591 0.0145
ICS, inhaled corticosteroid; OSI, osteo sono-assessment index.
male ICS users, 1st and 2nd %OSI were 98.3 +- 12.2
and 97.7 +- 13.4, and 101.4 +- 13.9, 101.8 +- 12.4%,
respectively (Table 4b). Those in the female controls
and ICS users were 102.8 +- 11.5 and 102.8 +- 13.4,
and 103.9 +- 10.4 and 102.3 +- 9.9%, respectively
(Table 4c). There were no significant differences in
1st %OSI and 2nd %OSI between the control subjects
and the ICS users in a gender-segregated compari-
son. There were no significant changes from 1st
%OSI to 2nd %OSI in both all the control subjects and
all the ICS users (Table 4a). In the male controls and
male ICS users, there were also no significant
changes from 1st %OSI to 2nd %OSI (Table 4b). Al-
though there were no significant changes in the fe-
male controls, 2nd %OSI decreased significantly com-
pared with 1st %OSI in the female ICS users (Table
4c). When the systemic corticosteroid users were ex-
cluded, the results were same (data not shown). The-
ses findings indicate that bone status was impaired
during 6 months of ICS use in females.
DISCUSSION
Recently, excellent pharmacotherapies, such as
bisphosphonates, have been developed, and they
have certain preventive effects against pathological
fractures due to osteoporosis.41,42 Therefore, it is very
important and meaningful to evaluate bone status for
adults while managing various diseases. To prevent
pathological fractures in the femoral neck, which can
be one of the causes of death in the elderly,33 world-
Assessment of Bone Status in ICS Users
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wide guidelines have been proposed based on an
evaluation of bone status.43 In Japan, guidelines have
also been made, indicating criteria for starting phar-
macotherapy in order to prevent pathological frac-
tures in idiopathic osteoporosis.44 According to these
Japanese guidelines, pharmacotherapy should princi-
pally begin for adults when they have a BMD of un-
der 70% of the mean of BMDs of those aged from 20
to 44 years old (YAM) without pathological fractures.
However, another kind of criterion has also been pro-
posed for systematic corticosteroid-administrated
cases, because systemic use of corticosteroids has
been clearly proven to have a negative impact on
bone status.45 In such cases, pharmacotherapy is
started whenever there is systemic use of corticoster-
oids at doses of more than 5 mgday prednisolone
(PSL) equivalent, and when a BMD of lower than 80%
of YAM at doses of lower than 5 mgday PSL equiva-
lent.
In this study, we evaluated the right individual cal-
caneus, giving rise to the question of whether the oc-
currence of pathological femoral neck fractures can
be estimated by the measurement of calcaneus bone
status. However, the evaluation of calcaneus bone
status using quantitative ultrasound as used in this
study has been reported to be an excellent predictor
of femoral neck fractures.46,47 In the present study, a
significant deterioration of bone status in female ICS
users over a short duration of only 6 months indi-
cated that the standard 6 month asthma management
in the actual clinical setting could impaire the female
patient’s bone status and that the use of ICS might
play an important role in this decrease of %OSI. As we
did not examine both the ICS use history of asthmatic
patients perior to this study and transient use of sys-
temic corticosteroids due to asthma exacervation dur-
ing the study period, it may be difficult to conclude
that the ICS use of 6 months impare the bone status
of female asthmatic patients. However, it is possible
to show that a female asthmatic patient under at least
6 momths standard asthma management including
ICS therapy may be as same as a systemic corti-
costeroid user at lower dose. Therefore, evaluation of
bone status, especially BMD value comparison with
that of YAM, should be considered for adult female
asthma patients at or 6 months after initiation of
asthma management including ICS therapy. How-
ever, there were no significant changes observed dur-
ing the 6 months in males, indicating that early pre-
vention of osteoporosis may be unnecessary soon af-
ter the start of ICS therapy in male asthma patients.
Although we also examined the relationship be-
tween the daily ICS dose and the changes of %OSI in
each asthmatic patient, there was no significant rela-
tionship (data not shown). In female patients, it was
thought that not daily ICS dose but the ICS use itself
at the usual dose of ICS might play an essential role
in the changes of %OSI. Regarding to the doses of
ICS of the male and female patients, there was no sig-
nificant changes of %OSI between 1st and 2nd %OSI
in male patients despite of significantly more ICS
dose (460 +- 214 mgday calculated as FP) than that
in female (392 +- mgday calculated as FP), indicat-
ing that there was little impact on the male bone
status within 6 months asthma management, includ-
ing ICS therapy, in the actual clinical setting. There
was no significant difference of 1st %OSI between fe-
male controls and patients. There was no suitable ex-
planation for it, because the mean disease duration in
female patients was 8.9 years and because a certain
influence of ICS use prior to this study on only female
patients was supposed. The compliance of ICS during
the study period was not investigated in this study.
However, because we reported that the ICS compli-
ance of male and older patients was better than that
of female and younger48 in the actual clinical setting,
there was nothing controversial as for ICS compli-
ance. Other potent predictive factors for bone status,
including smoking status, were not analyzed in this
study. However, the incidence of smoking in female
asthma patients has been reported to be 7.4%49 and is
obviously less than that reported for the general fe-
male population. This indicates that the results of the
present study, namely that a management of asthma,
incuding ICS use, can affect bone status in female
asthma patients, is not likely to be greatly influenced
by the exclusion of smoking status.
In summary, this study found there to be no signifi-
cant changes between male ICS users and control
subjects. However, the 6-month management of
asthma in the actual clinical setting, including ICS
use, might have a harmful influence on the bone
status of female asthmatic patients, indicating that it
may be necessary to manage and treat female pa-
tients for potent corticosteroid-induced osteoporosis,
although further analyses of bone status in asthma
patient ICS users will be required.
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